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Abstract
Background: Given the elevated risk of cardiovascular events and the higher prevalence of silent coronary artery
disease (CAD) in diabetic versus non-diabetic patients, the need to screen asymptomatic diabetic patients for CAD
assumes increasing importante. The aims of the study were to assess prospectively the prevalence and risk factor
predictors of true silent myocardial ischemia (myocardial perfusion defects in the absence of both angina and
ST-segment depression) in asymptomatic type 2 diabetic patients.
Methods: Stress myocardial perfusion gated SPECT (Single Photon Emission Computed Tomography) was carried
out in 41 type 2 diabetic patients without history of cardiovascular disease (CVD) and 41 nondiabetic patients
matched by age and gender.
Results: There were no significant differences between the two groups regarding either the classic CVD risk factors
or left ventricular function. True silent ischemia was detected in 21.9% of diabetic patients but only in 2.4% of
controls (p < 0.01). The presence of myocardial perfusion defects was independently associated with male gender
and the presence of diabetic retinopathy (DR). The probability of having myocardial perfusion defects in an
asymptomatic diabetic patient with DR in comparison with diabetic patients without DR was 11.7 [IC95%: 3.7-37].
Conclusions: True silent myocardial ischemia is a high prevalent condition in asymptomatic type 2 diabetic
patients. Male gender and the presence of DR are the risk factors related to its development.
Background
Patients with diabetes, in particular with type 2 diabetes,
are at a 2- to 4- fold higher risk of cardiovascular mortal-
ity compared with nondiabetic subjects. In addition, dia-
betic patients are less likely to survive a first myocardial
infarction than their nondiabetic peers. Therefore, early
identification of coronary artery disease (CAD) in the
diabetic population is needed. However, the fact that
CAD is often asymptomatic in diabetic patients makes
such identification a challenge. A number of studies have
shown that silent myocardial ischemia - as evidenced by
non-invasive tests such as the electrocardiogram stress
test, myocardial scintigraphy or stress echocardiography-
affects 20-50% of diabetic patients with additional risk
factors [1]. The term of silent ischemia includes an entity
named true silent myocardial ischemia or clandestine
ischemia, which is characterized by myocardial perfusion
defects in the absence of both angina and ST-segment
depression > 1 mm during the exercise test. To the best
of our knowledge there have been no studies addressed
to determining its prevalence and the risk factors asso-
ciated with its development.
In the largest study performed until now to evaluate
the prevalence of silent myocardial ischemia in diabetic
patients, the DIAD (Detection of Ischaemia in Assymp-
tomatic Diabetics) study [2] patients with silent
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myocardial ischemia were analyzed all together. After
careful examination of the results one can deduce that
14% of the patients allocated to be screened with stress
myocardial perfusion imaging had true silent myocardial
ischemia. However, a control group of non-diabetic
subjects was not included and, therefore, it is not possi-
ble to know how often assymptomatic diabetic patients
have defects of myocardial perfusion in comparison with
non-diabetic population.
The present case-control study was designed to assess
prospectively the prevalence and risk factor predictors
of true silent myocardial ischemia in asymptomatic type
2 diabetic patients without a history of cardiovascular
disease (CVD).
Methods
Subjects
This study has been performed following the “Strength-
ening the Reporting of Observational Studies in Epide-
miology” (STROBE) guidelines for reporting case-control
studies [3].
Sample size calculation
W eu s e dt h ef o l l o w i n gf o r m u l af o rt h es a m p l es i z e
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n= estimated necessary sample size
Za = Z-coefficient for Type I error
Zb = Z-coefficient for Type II error
p1 = estimated proportion of myocardial perfussion
defects in controls (non diabetic population)
p2 = estimated proportion of myocardial perfussion
defects in cases (diabetic patients)
p = mean value of p1 and p2
For this purpose we estimated ap r i o r ithat the preva-
lence of true silent ischemia would be of 2% (p1 =0 . 0 2 )
in nondiabetic subjects and 20% (p2 = 0.20) in diabetic
patients. We used a 5% of significance level and a power
of 80%. The specific figures are displayed below:
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Therefore, the minimum sample size was 36 subjects
in each group.
Exclusion criteria
Exclusion criteria were: 1) history of CVD; 2) electrocar-
diographic evidence of Q-wave myocardial infarction,
ischemic ST depression, T-wave changes, or complete
left bundle branch block; 3) flat or downsloping ST seg-
ment depression > 1 mm at 80 ms after the J-point
during an exercise test on a bicycle ergometer. On this
basis 44 consecutive asymptomatic type 2 diabetic
patients were propectively recruited from our outpatient
diabetes clinic (Figure 1). Three patients were excluded
from the study because they presented ST-segment
depression > 1 mm during exercise test. Forty-one non-
diabetic subjects matched by age and gender were
selected as a control group.
This study was approved by the hospital’sh u m a n
ethics committee and conducted according to the prin-
ciples expressed in the Declaration of Helsinki. Written
informed consent was obtained from all patients.
Stress myocardial perfusion imaging
All patients were systematically screened with an exer-
cise test on a bicycle ergometer and stress myocardial
perfusion imaging using technetium-99m-methoxy-
isobutyl-isonitrile single-photon emission computed
tomography (SPECT). All patients did symptom-limited
exercise on a stationary bicycle. One-day protocol gated
SPECT was used: a first dose of 8 mCi, given 30-60 sec-
onds before finishing exercise, and a second dose of
24 mCi, administered at rest, were separated by an
interval of more than 45 minutes. The equipment used
was a Siemens E-CAM dual head 90° gamma camera
with a low energy high-resolution collimator and 180°
semicircular orbit set in “step-and-shoot” mode, initiated
at 45° right anterior oblique, with images every 3 degrees
(25 second time frame). Acquisition was synchronized
with the electrocardiogram R wave, with an 8 frame/car-
diac cycle. Frames were reconstructed with this gamma
camera using filtered backprojection (Butterworth filter,
Type 2 diabetic patients
Potential participants;  N=61
Excluded by not meeting inclusion criteria; N=15
Eligible patients;  N=46
Ref sed to participate; N 2
yg ;
Refused to participate; N=2
Patients included in the study;  N=44
Excluded by ST ischemic depression
during stress test; N=3    
Analyzed Patients; N=41 Analyzed Patients; N=41
Figure 1 Flow chart showing the patients included in the study.
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Page 2 of 7(order 10, cutoff frequency 0.35 for stress, and order 10,
cutoff frequency 0,45 for rest). To quantify perfusion
the left ventricle was divided into 17 segments, each of
which was assigned a score from 0 to 4 (0 = normal
perfusion, 1 = mild hypoperfusion, 2 = moderate hypo-
perfusion, 3 = severe hypoperfusion, and 4 = no
uptake). The summed stress score and summed rest
s c o r ew e r eo b t a i n e d ,w i t ht h es u m m e dd i f f e r e n c es c o r e
being the difference between the two. An ischemic
patient was defined as showing the presence of a
summed difference score ≥ 2. A moderate perfusion
defect was defined as a segmental score ≥ 2i n>1s e g -
ment, and severe perfusion defect was defined as a seg-
mental score ≥ 3 in > 1 segment in stress images [4,5].
Calculation of left ventricular ejection fraction and ven-
tricular volumes was automatically performed during
rest gated SPECT. Endocardial and epicardial bound-
aries were automatically traced using the quantitative
QGS
® software (Cedars-Sinai Medical Center, Los
Angeles, CA USA) [6].
Cardiovascular risk factors and diabetic retinopathy (DR)
assessment
The cardiovascular risk factors evaluated were: obesity
(defined as body mass index ≥30 Kg/m
2), smoking habit
(past or current), hypertension (defined as blood pres-
sure > 140/90 mmHg or anti-hypertensive drug use),
dyslipemia (defined as lipid abnormalities or lipid-
lowering treatment), and diagnosis of CAD in parents or
sibling before age 50.
Fundoscopic examination in mydriasis using slit lamp
biomicroscopy was conducted by the same ophthalmolo-
gist who was unaware of the clinical status of the
patient. In addition seven-standard field color retinal
photographs were taken using a digital camera (Topcon
TCR-50DX). The elapsed time between fundoscopic
examination and gated SPECT was less than four weeks
in all cases. For DR classification the International Clini-
cal Diabetic Retinopathy Severity Scale was used [7].
Blood and urine samples were obtained for laboratory
testing. The main clinical data of both groups are dis-
played in Table 1.
Statistical analysis
Bivariate associations were tested using t test and Fisher’s
exact test. To identify the factors independently related
with clandestine ischemia a backward stepwise logistic
regression analysis was performed.
Results
Apart from diabetes there were no significant differences
between the two groups regarding either the classic CVD
risk factors (age, gender, smoking habit, dyslipemia,
hypertension, and family history of CAD) or left ventricu-
lar function (Table 1). Diabetic patients presented lower
levels of LDL-cholesterol than control subjects. The use
of statins was higher in diabetic patients than in the con-
trol group (73% vs. 51%; p < 0.05).
Three out of 44 recruited patients were excluded from
the study because they presented ST-segment depres-
sion > 1 mm during exercise test (Figure 1). True silent
myocardial ischemia was detected in 9 out of 41 (21.9%)
type 2 diabetic patients (1 with moderate and 8 with
mild perfusion defects) but only in one (mild perfusion
defects) out of 41 controls (2.4%), (p < 0.01). Represen-
tative images of normal myocardial perfusion SPECT in
non-diabetic subject, and mild and moderate perfusion
defects detected in diabetic patients can be observed in
figure 2. It should be noted that in the diabetic patient
with inferior moderate perfusion defect a coronary
angiography was performed and a <50% stenosis of right
coronary artery was found.
Table 1 Clinical, ergometric and scintigraphic
characteristics of subjects included in the study
Diabetic
Patients
Controls
n = 41 n = 41 p
Age (years) 63.0 ± 5.4 61.1 ± 6.1 0.1
Male/Female (n) 11/30 11/30 0.59
Obesity
a (%) 48.8% 34.14% 0.26
Smoking
b (%) 19.5% 21.9% 0.95
Hypertension
c (%) 56% 36.6% 0.12
Dyslipemia
d (%) 73.1% 63.4% 0.33
Family history of CAD
e (%) 14.6% 17.1% 0.5
Duration of diabetes (years) 11.0 ± 7.2 -
Retinopathy (%) 17.1% -
Nephropathy (%) 9.7% -
Neuropathy (%) 2.4% -
Laboratory parameters:
Glucose (mg/dl) 162 ± 6 98 ± 9 <0.001
HbA1c (%) 8.2 ±1.3 5.8 ± 0.1 <0.001
AER (μg/minute) 6 [2-44] 5 [2-26] 0.73
Total-C (mg/dl) 206 ± 45 228 ± 39 0.06
HDL-C (mg/dl) 56 ± 10 55 ± 10 0.71
LDL-C (mg/dl) 121 ± 38 167 ± 19 <0.001
Triglycerides (mg/dl) 139 [65-242] 125 [66-175] 0.24
Exercise test:
METs 6.74 ± 2.01 7.01 ± 1.78 0.60
Peak heart rate (bpm) 136 ± 14 138 ± 14 0.54
Peak systolic blood pressure
(mmHg)
179 ± 24 172 ± 17 0.25
Gated-SPECT:
Ejection fraction (%) 74.3 ± 11.1 72.6 ± 8.1 0.51
LV end-diastolic volume (ml) 57.6 ± 17.9 64.6 ± 14.6 0.12
LV end-systolic volume (ml) 16.4 ± 11.8 19.4 ± 8.6 0.30
Data are expressed as the mean ± SD or median [range]; bpm: beats per
minute; LV: left ventricular; METs: Estimated Metabolic Equivalent.
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fusion defects was 54.5% in male patients and 13.3% in
females (p = 0.01). In addition, the prevalence of true
silent ischemia in diabetic patients with DR was signifi-
cantly higher than in diabetic patients without DR (50%
vs. 13%; p = 0.04). On the other hand, DR was higher in
patients with true silent myocardial ischemia than in
patients without it (40% vs. 9.6%; p = 0.04).
In the logistic regression analysis, both male gender
and DR were independently associated with the pre-
sence of true silent myocardial ischemia (Table 2).
Finally, we did not find any differences either in left
ventricular volumes (end-systolic and end-diastolic) or
in left ejection fraction between diabetic patients with
and without myocardial perfusion defects measured dur-
ing rest gated SPECT.
Discussion
In this case-control study we evaluated for the first time
t h ep r e v a l e n c eo ft r u es i l e n tm y o c a r d i a li s c h e m i ai n
asymptomatic type 2 diabetic patients in comparison
with a non-diabetic control group. Risk factors of CVD
were similar between both groups. However, diabetic
patients presented lower levels of LDL-cholesterol, this
being accounted by the use of statins. We found that
the prevalence of true silent myocardial ischemia is
strikingly higher than in their nondiabetic peers. As pre-
viously reported in silent myocardial ischemia [2], men
are more likely to have perfusion defects. Moreover, as
occurs in silent ischemia the number of traditional risk
factors is not useful as a means of identifying patients
with true silent myocardial ischemia [2,8,9].
One of the most important findings of the present
study is that DR is independently associated with the
presence of true silent myocardial ischemia. In this
regard, DR has been recently recognized as an indicator
of risk for CAD in diabetic patients [10-12] and it is
predictive of cardiovascular mortality [13,14]. Our
results are consistent with other observations supporting
the concept that micro and macrovascular complications
of diabetes share common pathogenic mecanisms
beyond those related to the classical risk factors
[10,13,15]. The common pathogenic mechanisms
between micro and macrovascular complications are
uncertain but there is emerging evidence to suggest that
DR has common genetic linkages with systemic vascular
complications [11]. In addition, endothelial dysfunction,
platelet dysfunction, oxidative stress, inflammation, and
advanced glycation end products are pathogenic factors
Figure 2 Images corresponding to myocardial perfusion SPECT
obtained in diabetic and non-diabetic control subjects. A)
Normal SPECT in a representative non-diabetic subject. B) Mild
reversible defect in the left ventricular antero-apical region (SDS=3) in
a representative type 2 diabetic patient. C) Moderate reversible defect
in the left ventricular inferior region (SDS=5) in a representative type 2
diabetic patient. HLA: Horizontal Long Axis, R: Rest, S: Stress, SA: Short
Axis, SDS: Summed Difference Score, SRS: Summed Rest Score, SSS:
Summed Stress Score, VLA: Vertical Long Axis.
Table 2 Logistic regression analysis showing the
independent predictors of true silent myocardial
ischemia in diabetic subjects
Variable Odds ratio [95% CI] p
Male gender (no/yes) 3.3 [1.2-8.5] 0.02
Diabetic retinopathy (no/yes) 11.7 [3.7-37] 0.03
Age (years) 1.03 [0.8-1.28] 0.79
HbA1C (%) 0.67 [-0.42-1.76] 0.57
Diabetes duration (years) 0.82 [0.59-1.05] 0.08
Plama cholesterol (mg/dl) 1.01 [0.98-1.04] 0.44
Smoking habit (no/yes) 0.20 [-3.01-3.41] 0.79
Apart from the variables associated with true silent ischemia in univariate
analysis (gender, diabetic retinopathy), HbA1c, diabetes duration, and classic
cardiovascular risk factors (age, plasma cholesterol, hypertension and smoking
habit) were also entered in the logistic regression analysis.
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betic patients [13,15]. Furthermore, DR reflects wide-
spread microcirculatory disease not only in the eye but
also in vital organs elsewhere in the body such as myo-
cardium. For all these reasons it is not surprising that
type 2 diabetic patients with DR present a higher preva-
lence of myocardial perfusion defects in comparison
with those patients without DR. However, in the DIAD
study DR was not predictive of myocardial perfusion
defects. The reasons why our findings are not coincident
with DIAD remain to be elucidated, but it should be
noted that in our study ophthalmoscopic examinations
were performed in all cases within the same month as
stress myocardial perfusion gated-SPECT and using the
same method. By contrast, the methods for the assess-
ment of DR described in the DIAD study were non-
homogeneous and the time elapsed between fundoscopy
and SPECT was not specified.
One might wonder which diabetic patients would ben-
efit from a SPECT for ruling out a silent ischemia and
whether the information drawn from this test might be
beneficial in terms of CAD prognosis. This is important
not only for the management of diabetic patients but
also in economic terms. In this regard, the main aim of
the DIAD study was to test the hypothesis that systema-
tic screening with stress myocardial perfusion imaging
would identify higher-risk individuals and beneficially
affect their risk of myocardial infarction or cardiac
death. The conclusion of the study was that the identifi-
cation of patients with myocardial perfusion defects did
not serve to lower their risk over 5 years of follow-up
[16]. However, the DIAD study was not designed as a
treatment trial and did not recommend coronary angio-
graphy or any specific treatment plan for patients with
abnormal screening tests. In fact, the number of coron-
ary angiograms performed during follow-up was similar
in the screened and in the non-screened group. More-
over, the use of statins, angiotensin-converting enzyme
inhibitors, antihypertensive and antihyperglycemic medi-
cations, and aspirin for primary medical prevention was
the same for screened and non-screened patients.
Therefore, it is logical that the screening process per se
used in the DIAD study did not improve the clinical
outcomes of diabetic patients. By contrast, in another
randomised study also including asymptomatic type 2
diabetic patients, it has been observed that the rate of
cardiac events was significantly lower in patients
screened for silent myocardial ischemia and revascular-
ized when necessary than in patients who were not
screened [17]. In this study the protocol consisted in
performing an exercice electrocardiogram test and
dypiridamole stress echocardiography. If one of these
tests were abnormal, a coronariography was then per-
formed, and revascularization procedure was indicated
in the case of stenoses ≥ 50% of vessel lumen. Using
this scheduled management, no cardiac events occurred
in patients who underwent revascularization procedures
at the time of screening during the 5 years of follow-up.
Finally, Mohagheghie et al recently found that 1/3
patients with diabetes mellitus without abnormal ECG
findings and with myocardial perfusion defects pre-
sented occult CAD [18].
Although cost-effectiveness studies are still needed it
is undeniable that type 2 diabetes could benefit from
the identification of silent myocardial ischemia. In fact,
a normal SPECT has a very high negative predictive
value for myocardial infarction or cardiac death [19]. In
addition, in the DIAD study asymptomatic diabetic
patients with moderate or large myocardial perfusion
defects had a 6-fold greater cardiac risk than those with
normal studies or small defects [16]. However, the
meaning of a positive SPECT in the setting of true
silent myocardial ischemia, in particular when perfusion
deficits are of mild intensity, remains to be elucidated.
Meanwhile, in terms of clinical practice it would be rea-
sonable to be especially rigorous in achieving a tight
control of risk factors and blood glucose in these
patients. In this regard it should be underlined that in
the DIAD study, a more intensive treatment of cardio-
vascular risk factors was associated with the resolution
of perfusion deficits [20].
The repercussion of true silent ischemia (in particular
mild perfusion defects) on cardiac function in diabetic
patients is a topic that remains to be elucidated. We did
not find any differences either in left ventricular
volumes (end-systolic and end-diastolic) or in left ejec-
tion fraction between diabetic patients with and without
myocardial perfusion defects. However, it should be
noted that diabetes can be associated with impaired
myocardial performance assessed by echocardiographic
tissue Doppler imaging even in the absence of signifi-
cant CAD [21]. In addition, Hallén et al [22] have
recently found in a relatively young and healthy type 2
diabetic population elevations of cardiac troponin with a
clear trend toward adverse outcomes. Specific studies
addressed to exploring whether these findings are more
frequent in diabetic patients with myocardial perfusion
defects are needed.
Given that a generalized screening of asymptomatic
type 2 diabetic patients with stress myocardial perfusion
imaging is not a realistic approach [23], we wanted to
identify the most relevant risk factors associated with
clandestine ischemia. We found that the presence of DR
and male gender were independently related to the pre-
sence of myocardial perfusion defects in type 2 diabetic
patients. The probability of having myocardial perfusion
defects in an asymptomatic diabetic patient with DR
was 11.7 [IC95%: 3.7-37] in comparison with diabetic
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good target population for indicating SPECT. This infor-
mation is important not only for the management of
diabetic patients but also in terms of the economic bur-
den. The current guidelines already identify the need for
routine screening for DR. In addition to appropriate
vision care, the detection of DR might now also warrant
a fuller cardiac evaluation and closer follow-up to pre-
vent the development of CAD.
Our results could also have therapeutic implications.
There is now emerging evidence that intravitreal anti-
VEGF (vascular endothelial growth factor) agents
(ie. pegaptamib, ranibizumab, bevacizumab) are useful in
the management of advanced DR [24]. However, anti-
VEGF drugs injected into the vitreous could pass into
systemic circulation and could compromise the capacity
of collateral vessel development and cardiac remodelling
[24,25]. It is well-established that high levels of VEGF
and its receptors are observed in DR and in diabetic
nephropathy, and this is particularly crucial for the
development of DR. By contrast, low levels of VEGF
and its receptors are found in the myocardium of dia-
betic patients [26,27], resulting in inadequate collateral
formation. Therefore, diabetic patients with perfusion
defects might be more prone to the development of
myocardial ischemia if circulating VEGF is blocked. In
consequence, patients with advanced DR requiring anti-
VEGF treatment could be a selected group for whom
stress myocardial perfusion gated SPECT could be spe-
cially indicated.
Conclusions
We conclude that true silent myocardial ischemia is fre-
quent in asymptomatic type 2 diabetic patients. In addi-
tion, DR is a high risk condition for true silent
myocardial ischemia in asymptomatic type 2 diabetic
patients, and point to these patients as a target to be
screened for CAD. Further prospective studies evaluat-
ing the prognostic value of these findings and their
impact in economical terms are warranted.
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